TITLE

Ustekinumab Injection (Stelara)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
December 2009
SOURCE
Internal Medicine Alert;12/15/2009, Vol. 31 Issue 23, p181
SOURCE TYPE
Periodical
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the monoclonal antibody Usketinumab injection from Centocor Ortho Biotech Inc.
ACCESSION #
47507393

 

Related Articles

  • Golimumab: A new TNF-alpha blocker. Tanzi, Maria G. // Pharmacy Today;Jun2009, Vol. 15 Issue 6, p34 

    The article evaluates Golimumab (Simponi), a new tumor necrosis factor (TNF)-alpha blocker from Centocor Ortho Biotech Inc.

  • Morphotek signs licensing agreement with Centocor Ortho Biotech.  // PharmaWatch: Biotechnology;Dec2009, Vol. 8 Issue 12, p20 

    The article reports that Morphotek Inc. has signed a license agreement with healthcare firm Centocor Ortho Biotech Inc. in the U.S. It states that the agreement aims to develop an antibody for a tumor-associated antigen over-expressed in many solid tumors. It adds that the agreement will provide...

  • Patent Watch. Harrison, Charlotte // Nature Reviews Drug Discovery;Apr2011, Vol. 10 Issue 4, p250 

    The article reports on developments in patent applications and litigations within Europe and the U.S. The proposal to create the European Patent Court marks the attempt to establish a unified European patent litigation system. Some claims in a patent owned by Centocor Ortho Biotech Inc. are...

  • COMPANY SPOTLIGHT -- Centocor Ortho Biotech.  // PharmaWatch: Biotechnology;Aug2009, Vol. 8 Issue 8, p30 

    The article presents a company profile for Centocor Ortho Biotech Inc., a subsidiary of Johnson & Johnson in the biotechnology industry in the U.S. It provides an overview on the business condition, developments and engagements of Centocor, focusing on the company's operation in the development...

  • STELARA.  // Monthly Prescribing Reference;Nov2009, Vol. 25 Issue 11, pA19 

    The article evaluates the drug Stelara from Centocor Ortho Biotech Inc.

  • Gastrointestinal disorders.  // Formulary;Sep2009, Vol. 44 Issue 9, p280 

    The article evaluates several medicines for gastrointestinal disorders including the CCX282 Traflcet-EN from ChemoCentryx Inc., the Prochymal mesenchymal stem cell product from Osiris Pharmaceuticals Inc. and the usteklnumab from Centocor Ortho Biotech Inc.

  • New products.  // Drug Topics;Jun2011, Vol. 155 Issue 6, p63 

    The article offers information on several drugs including abiraterone acetate (Zytiga) from Centocor Ortho Biotech Inc., sodium ferric gluconate complex (Nufecit) from Watson Pharmaceuticals Inc. and the testosterone gel AndroGel from Abbott Laboratories Inc.

  • FDA Approves Biologic to Treat Psoriasis.  // BioPharm International;Nov2009, Vol. 23 Issue 11, p14 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Stelara from Centocor Ortho Biotech Inc. to treat psoriasis. It notes that the drug blocks the action of two proteins contributing to the overproduction of skin cells and inflammation. It points out that FDA...

  • FDA Update.  // Pharmaceutical Representative;Jun2011, Vol. 41 Issue 6, p11 

    The article offers updates relative to the U.S. Food and Drug Administration. FDA has engaged a series of studies designed to test varied ways of demonstrating the benefits and risks in direct-to-consumer (DTC) promotion of prescription drugs. FDA has approved Centocor Ortho Biotech Inc.'s...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics